Onderneming Arrowhead Research Corp Nasdaq
Aandelen
US0427972098
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Drugs
100,0
%
| 243 | 100,0 % | 241 | 100,0 % | -1,03% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 243 | 100,0 % | 241 | 100,0 % | -1,03% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 01-12-07 | |
Director of Finance/CFO | 57 | 01-01-09 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-22 |
Patrick O'brien
CMP | Compliance Officer | 60 | 01-12-14 |
Bruce Given
COO | Chief Operating Officer | 69 | 26-10-11 |
Vincent Anzalone
IRC | Investor Relations Contact | - | - |
Aaron Tan
AUD | Comptroller/Controller/Auditor | - | 01-07-21 |
Nadia Meshkova
TRE | Treasurer | - | - |
Tracie Oliver
PRN | Corporate Officer/Principal | 62 | 01-06-22 |
Matt Pulisic
PRN | Corporate Officer/Principal | - | 01-08-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 23-11-10 |
Michael Perry
BRD | Director/Board Member | 64 | 19-12-11 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 01-09-20 |
Hong Bo Lu
BRD | Director/Board Member | 53 | 01/04 |
Chief Executive Officer | 54 | 01-12-07 | |
William Waddill
BRD | Director/Board Member | 67 | 01-01-18 |
Mauro Ferrari
BRD | Director/Board Member | 64 | 19-08-10 |
Director/Board Member | 60 | 02-05-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 124 200 230 | 118 638 599 ( 95,52 %) | 0 | 95,52 % |
Bedrijfsgegevens
Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard Suite 700
91105, Pasadena
+626 304 3400
http://www.arrowheadpharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,52% | 113 mld. | |
+11,38% | 106 mld. | |
+0,76% | 22,27 mld. | |
-12,64% | 22,22 mld. | |
-4,50% | 19,43 mld. | |
-37,85% | 17,87 mld. | |
-8,58% | 17,24 mld. | |
+7,77% | 14,29 mld. | |
+37,41% | 12,52 mld. |